Do non‐steroidal anti‐inflammatory drugs influence chronic inflammation? The effects of piroxicam on chronic antigen‐induced arthritis in rats

References

• Schlesinger N. Management of acute and chronic gouty arthritis: present state‐of‐the‐art. Drugs 2004; 64: 2399–416
   PubMed Web of Science ®Google Scholar
• Lopez‐Armada M. J., Sanchez‐Pernaute O., Largo R., Diez‐Ortego I., Palacios I., Egido J., et al. Modulation of cell recruitment by anti‐inflammatory agents in antigen‐induced arthritis. Ann Rheum Dis 2002; 61: 1027–30
   PubMed Web of Science ®Google Scholar
• de Vries B. J., van den Berg W. B. Impact of NSAIDs on murine antigen induced arthritis. I. An investigation of antiinflammatory and chondroprotective effects. J Rheumatol 1989; 16((Suppl 18))10–16
   Google Scholar
• Gebhard H. H., Zysk S. P., Schmitt‐Sody M., Jansson V., Messmer K., Veihelmann A. The effects of celecoxib on inflammation and synovial microcirculation in murine antigen‐induced arthritis. Clin Exp Rheumatol 2005; 22: 63–70
   Google Scholar
• Abu‐Shakra M., Toker R., Flusser D., Flusser G., Friger M., Sukenik S., et al. Clinical and radiographic outcomes of rheumatoid arthritis patients not treated with disease modifying drugs. Arthritis Rheum 1998; 41: 1190–5
   PubMedGoogle Scholar
• Menkes C. J. Effects of disease‐modifying anti‐rheumatic drugs, steroids and non‐steroidal anti‐inflammatory drugs on acute‐phase proteins in rheumatoid arthritis. Br J Rheumatol 1993; 32((Suppl 3))14–18
   PubMedGoogle Scholar
• Garcia‐Vicuna R., Diaz‐Gonzalez F., Gonzalez‐Alvaro I., del Pozo M. A., Mollinedo F., Cabanas C., et al. Prevention of cytokine‐induced changes in leukocyte adhesion receptors by nonsteroidal antiinflammatory drugs from the oxicam family. Arthritis Rheum 1997; 40: 143–53
   PubMedGoogle Scholar
• Gonzalez‐Alvaro I., Munoz C., Garcia‐Vicuna R., Sabando P., Cabanas C., Sanchez‐Madrid F., et al. Interference of nonsteroidal anti‐inflammatory drugs with very late activation antigen 4/vascular cells adhesion molecule 1‐mediated lymphocyte‐endothelial cell adhesion. Arthritis Rheum 1998; 41: 1677–88
   PubMedGoogle Scholar
• Härtel C., von Puttkamer J., Gallner F., Strunk T., Schultz C. Dose‐dependent immunomodulatory effects of acetylsalicylic acid and indomethacin in human whole blood: potential role of cyclooxygenase‐2 inhibition. Scand J Immunol 2004; 60: 412–20
   PubMed Web of Science ®Google Scholar
• Sironi M., Gadina M., Kankova M., Riganti F., Mantovani A., Zandalasini M., et al. Differential sensitivity of in vivo TNF and IL‐6 production to modulation by anti‐inflammatory drugs in mice. Int J Immunopharmacol 1992; 14: 1045–50
   PubMed Web of Science ®Google Scholar
• Rainsford K. D., Ying C., Smith F. C. Effects of meloxicam, compared with other NSAIDs, on cartilage proteoglycan metabolism, synovial prostaglandin E2, and production of interleukins 1, 6 and 8, in human and porcine explants in organ culture. J Pharm Pharmacol 1997; 49: 991–8
   PubMed Web of Science ®Google Scholar
• Reijman M., Bierma‐Zeinstra S. M., Pols H. A., Koes B. W., Stricker B. H., Hazes J. M. Is there an association between the use of different types of nonsteroidal anti‐inflammatory drugs and radiologic progression of osteoarthritis? The Rotterdam Study. Arthritis Rheum 2006; 52: 3137–42
   Google Scholar
• Muller‐Decker K., Hirschner W., Marks F., Furstenberger G. The effects of cyclooxygenase isozyme inhibition on incisional wound healing in mouse skin. J Invest Dermatol 2002; 119: 1189–95
   PubMed Web of Science ®Google Scholar
• Bergenstock M., Min W., Simon A. M., Sabatino C., O'Connor J. P. A comparison between the effects of acetaminophen and celecoxib on bone fracture healing in rats. J Orthop Trauma 2005; 19: 717–23
   PubMed Web of Science ®Google Scholar
• Cohen D. B., Kawamura S., Ehteshami J. R., Rodeo S. A. Indomethacin and celecoxib impair rotator cuff tendon‐to‐bone healing. Am J Sport Med 2006; 34: 362–9
   PubMed Web of Science ®Google Scholar
• Postlethwaite A. E., Kang A. H., Myers J. K. NSAIDs abrogate oral tolerance (OT) induction to type II collagen (CII) in DBA/1 mice. Arthritis Rheum 1997; 40((Suppl 9))S54
   Google Scholar
• Louis E., Franchimont D., Deprez M., Lamproye A., Schaaf N., Machieu P., et al. Decrease in systemic tolerance to fed ovalbumin in indomethacin treated mice. Int Arch Allergy Immunol 1996; 109: 21–6
   PubMed Web of Science ®Google Scholar
• McKown K. M., Carbone L. D., Kaplan S. B., Aelion J. A., Lohr K. M., Cremer M. A., et al. Lack of efficacy of oral bovine type II collagen added to existing therapy in rheumatoid arthritis. Arthritis Rheum 1999; 42: 1204–8
   PubMed Web of Science ®Google Scholar
• Mamdani M., Juurlink D. N., Lee D. S., Rochon P. A., Kopp A., Naglie G., et al. Cyclo‐oxygenase‐2 inhibitors versus non‐selective non‐steroidal anti‐inflammatory drugs and congestive heart failure outcomes in elderly patients: a population‐based cohort study. Lancet 2004; 363: 1751–6
   PubMed Web of Science ®Google Scholar
• Singh G., Triadafilopoulos G. Epidemiology of NSAID‐induced gastro‐intestinal complications. J Rheumatol 1999; 26((Suppl 56))18–24
   Google Scholar
• Cooke T. D. V. Antigen‐induced arthritis, polyarthritis and tenosynovitis. CRC handbook of animal models for the rheumatic diseases, R. A Greenwald, H. S Diamond. CRC Press Inc, Boca Radon, FL 1988; 53–81, vol. 1
   Google Scholar
• Buchner R., Bräuer R., Schmidt C., Emmrich F., Kinne R. W. Induction of flare‐up reactions in rat antigen‐induced arthritis. J Autoimmun 1995; 8: 61–74
   PubMed Web of Science ®Google Scholar
• Idogawa H., Imamura A., Onda M., Umemura T., Ohashi M. Progression of articular destruction and the production of tumour necrosis factor‐α in antigen‐induced arthritis in rabbits. Scand J Immunol 1997; 46: 572–80
   PubMedGoogle Scholar
• van Meurs J. B. J., van Lent P. L. E. M., van de Loo A. A. J., Holthuysen A. E. M., Bayne E. K., Singer I. I., et al. Increased vulnerability of postarthritic cartilage to a second arthritic insult: accelerated MMP activity in a flare up of arthritis. Ann Rheum Dis 1999; 58: 350–6
   PubMedGoogle Scholar
• Yale Animal Resources Center. Veterinary clinical services. Analgesics and sedatives I–X, 2004, Available from: http://info.med.yale.edu/yarc/vcs/analgesics2.htm
   Google Scholar
• University of Pittsburgh. Institutional Animal Care and Use Committee, 2004, Available from: www.iacuc.pitt.edu/druglist.pdf
   Google Scholar
• Laneuville O., Breuer D. K., Dewitt D. L., Hla T., Funk C. D., Smith W. L. Differential inhibition of human prostaglandin endoperoxide H synthases‐1 and ‐2 by nonsteroidal anti‐inflammatory drugs. J Pharmacol Exp Ther 1994; 271: 927–34
   PubMed Web of Science ®Google Scholar
• Pirmohamed M., James S., Meakin S., Green C., Scott A. K., Walley T. J., et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18820 patients. Br Med J 2004; 329: 15–19
   PubMed Web of Science ®Google Scholar
• Wolfe F., Zhao S., Lane N. Preference for nonsteroidal anti‐inflammatory drugs over acetaminophen by rheumatic disease patients. Arthritis Rheum 2000; 43: 378–85
   PubMed Web of Science ®Google Scholar
• Seideman P., Melander A. Equianalgesic effects of paracetamol and indomethacin in rheumatoid arthritis. Br J Rheumatol 1988; 27: 117–22
   PubMedGoogle Scholar
• Kaplan H. B., Edelson H. S., Korchak H. M., Given W. P., Abramson S., Weissmann G. Effects of non‐steroidal anti‐inflammatory agents on human neutrophil functions in vitro and in vivo. Biochem Pharmacol 1984; 33: 371–8
   PubMed Web of Science ®Google Scholar
• van Epps D. E., Greiwe S., Potter J., Goodwin J. Alterations in neutrophil superoxide production following piroxicam therapy in patients with rheumatoid arthritis. Inflammation 1987; 11: 59–72
   PubMed Web of Science ®Google Scholar
• Biemond P., Han H., Swaak A. J. G., Koster J. F. Diminished superoxide production of synovial fluid neutrophils in patients with rheumatoid arthritis following piroxicam treatment. Scand J Rheumatol 1990; 19: 151–6
   PubMed Web of Science ®Google Scholar
• Haynes D. R., Wright P. F., Whitehouse M. W., Vernon‐Roberts B. The cyclo‐oxygenase inhibitor, piroxicam, enhances cytokine‐induced lymphocyte proliferation in vitro and in vivo. Immunol Cell Biol 1990; 68: 225–30
   PubMedGoogle Scholar
• Flescher E., Fossum D., Gray P. J., Fernandes G., Harper M. J. K., Talal N. Aspirin‐like drugs prime human T cells. Modulation of intracellular calcium concentrations. J Immunol 1991; 146: 2553–9
   PubMed Web of Science ®Google Scholar
• Serhan C. N., Savill J. Resolution of inflammation: the beginning programs the end. Nature Immunol 2005; 6: 1191–7
   PubMed Web of Science ®Google Scholar
• Levy B. D., Clish C. B., Schmidt B., Gronert K., Serhan C. N. Lipid mediator class switching during acute inflammation: signals in resolution. Nature Immunol 2001; 2: 612–19
   PubMed Web of Science ®Google Scholar
• Bandeira‐Melo C., Serra M. F., Diaz B. L., Cordeiro R. S. B., Silva P. M. R., Lenzi H. L., et al. Cyclooxygenase‐2‐derived prostaglandin E2 and lipoxin A4 accelerate resolution of allergic edema in Angiostrongylus costaricensis‐infected rats: relationship with concurrent eosinophilia. J Immunol 2000; 164: 1029–36
   PubMedGoogle Scholar
• Gilroy W. D., Colville‐Nash P. R., Willis D., Chivers J., Paul‐Clark M. J., Willoughby D. A. Inducible cyclooxygenase may have anti‐inflammatory properties. Nature Med 1999; 5: 698–701
   PubMed Web of Science ®Google Scholar
• Willoughby D. A., Moore A. R., Colville‐Nash P. R. Cyclopentenone prostaglandins – new allies in the war on inflammation. Nature Med 2000; 6: 137–8
   PubMed Web of Science ®Google Scholar
• Hurst S. M., Wilkinson T. S., McLoughlin R. M., Jones S., Horiuchi S., Yamamoto N., et al. IL‐6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity 2001; 14: 705–14
   PubMed Web of Science ®Google Scholar
• Marin. V., Montero‐Julian F. A., Gres S., Boulay V., Bongrand P., Farnarier C., et al. The IL‐6‐soluble IL‐6Rα autocrine loop of endothelial activation as an intermediate between acute and chronic inflammation: an experimental model involving thrombin. J Immunol 2001; 167: 3435–42
   PubMed Web of Science ®Google Scholar
• Reuben S. S., Ablett D., Kaye R. High‐dose nonsteroidal anti‐inflammatory drugs compromise spinal fusion. Can J Anaesth 2005; 52: 506–12
   PubMed Web of Science ®Google Scholar
• de Vries B. J., van den Berg W. B., Vitters E., van de Putte L. B. Effects of nonsteroidal anti‐inflammatory drugs on cartilage destruction in antigen‐induced arthritis in mice. Scand J Rheumatol 1988; 18((Suppl 77))23–8
   Google Scholar
• Hunneyball I. M., Crossley M. J., Spowage M. Pharmacological studies of antigen‐induced arthritis in BALB/c mice. I. Characterization of the arthritis and the effects of steroidal and non‐steroidal anti‐inflammatory agents. Agents Actions 1986; 18: 384–93
   PubMedGoogle Scholar
• Pettipher E. R., Hendersson B., Edwards J. C., Higgs G. A. Effect of indomethacin on swelling, lymphocyte influx, and cartilage proteoglycan depletion in experimental arthritis. Ann Rheum Dis 1989; 48: 623–7
   PubMedGoogle Scholar
• Goldlust M. B., Rich L. C. Chronic immune synovitis in rabbits. II. Modulation by anti‐inflammatory and anti‐rheumatic agents. Agents Actions 1981; 11: 729–35
   PubMedGoogle Scholar
• Smith R. J., Sly L. M. Type II collagen‐induced arthritis in the diabetic‐resistant biobreeding rat: inflammatory and histopathological features of joint pathology and effects of anti‐inflammatory and antirheumatic drugs on this chronic arthritic process. J Pharmacol Exp Ther 1996; 277: 1801–13
   PubMedGoogle Scholar
• Wooley P. H., Whalen J. D., Zimmerman J. L., Champion T. M. The effect of etodolac on type II collagen‐induced arthritis in mice. Agents Actions 1987; 21: 244–6
   PubMedGoogle Scholar
• Otterness I. G., Larson D. L., Lombardino J. G. An analysis of piroxicam in rodent models of arthritis. Agents Actions 1982; 12: 308–12
   PubMedGoogle Scholar